{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T10:48:29Z","timestamp":1790938109136,"version":"4.1.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T00:00:00Z","timestamp":1762732800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T00:00:00Z","timestamp":1762732800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Neurol Belg"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s13760-025-02945-2","type":"journal-article","created":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T15:42:00Z","timestamp":1762789320000},"page":"771-781","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Role of rituximab in treatment of patients with primary central nervous system lymphoma: An updated systematic review and meta-analysis"],"prefix":"10.1007","volume":"126","author":[{"given":"Kumail Mustafa","family":"Ali","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Farhan","family":"Ashraf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zain Ul","family":"Abideen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armish","family":"Rehman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rumman","family":"Javed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayena Ghulam","family":"Mujtaba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Touba","family":"Diwan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ukasha","family":"Khalid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laiba","family":"Ikram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,10]]},"reference":[{"issue":"21","key":"2945_CR1","doi-asserted-by":"publisher","first-page":"2410","DOI":"10.1200\/JCO.2017.72.7602","volume":"35","author":"C Grommes","year":"2017","unstructured":"Grommes C, DeAngelis LM (2017) Primary CNS, lymphoma. J Clin Oncol 35(21):2410\u20132418. https:\/\/doi.org\/10.1200\/JCO.2017.72.7602","journal-title":"J Clin Oncol"},{"key":"2945_CR2","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1182\/blood-2020-136427","volume":"136","author":"PA Haddad","year":"2020","unstructured":"Haddad PA, Hammoud D, Gallagher KM (2020) The impact of rituximab on the clinical outcomes of primary central nervous system lymphoma (PCNSL) when added to combination chemotherapy: a comprehensive meta-analysis. Blood 136:11\u201312","journal-title":"Blood"},{"key":"2945_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2019.116649","volume":"410","author":"PK Singh","year":"2020","unstructured":"Singh PK, Pan E (2020) Review of rituximab in primary CNS lymphoma. J Neurol Sci 410:116649. https:\/\/doi.org\/10.1016\/j.jns.2019.116649","journal-title":"J Neurol Sci"},{"issue":"9","key":"2945_CR4","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.1038\/bjc.2011.357","volume":"105","author":"JL Villano","year":"2011","unstructured":"Villano JL, Koshy M, Shaikh H, Dolecek TA, McCarthy BJ (2011) Age, gender, and racial differences in incidence and survival in primary CNS lymphoma. Br J Cancer 105(9):1414\u20131418. https:\/\/doi.org\/10.1038\/bjc.2011.357","journal-title":"Br J Cancer"},{"issue":"7","key":"2945_CR5","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","volume":"36","author":"R Alaggio","year":"2022","unstructured":"Alaggio R, Amador C, Anagnostopoulos I et al (2022) The 5th edition of the world health organization classification of haematolymphoid tumours: lymphoid neoplasms. Leukemia 36(7):1720\u20131748. https:\/\/doi.org\/10.1038\/s41375-022-01620-2","journal-title":"Leukemia"},{"issue":"8","key":"2945_CR6","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15082285","volume":"15","author":"KS Kurz","year":"2023","unstructured":"Kurz KS, Ott M, Kalmbach S et al (2023) Large b-cell lymphomas in the 5th edition of the WHO-classification of haematolymphoid neoplasms-updated classification and new concepts. Cancers (Basel). 15(8):2285. https:\/\/doi.org\/10.3390\/cancers15082285","journal-title":"Cancers (Basel)."},{"issue":"1","key":"2945_CR7","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-023-00439-0","volume":"9","author":"AJM Ferreri","year":"2023","unstructured":"Ferreri AJM, Calimeri T, Cwynarski K et al (2023) Primary central nervous system lymphoma. Nat Rev Dis Primers 9(1):29. https:\/\/doi.org\/10.1038\/s41572-023-00439-0","journal-title":"Nat Rev Dis Primers"},{"issue":"8","key":"2945_CR8","doi-asserted-by":"publisher","first-page":"2457","DOI":"10.1182\/blood.V84.8.2457.2457","volume":"84","author":"DG Maloney","year":"1994","unstructured":"Maloney DG, Liles TM, Czerwinski DK, Waldichuk C, Rosenberg J, Grillo-Lopez A, Levy R (1994) Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. Blood 84(8):2457\u20132466. https:\/\/doi.org\/10.1182\/blood.V84.8.2457.2457","journal-title":"Blood"},{"key":"2945_CR9","unstructured":"Raizer JJ, DeAngelis LM, Zelenetz A, Abrey EL (2000) Activity of rituximab in primary central nervous system lymphoma PCNSL. InProc Am Soc Clin Oncol. Vol. 19, p. 166a"},{"issue":"10","key":"2945_CR10","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1016\/j.clml.2023.06.008","volume":"23","author":"Y Zhang","year":"2023","unstructured":"Zhang Y, Liu Z, Gao C et al (2023) Role of rituximab in treatment of patients with primary central nervous system lymphoma (PCNSL): a systematic review and meta-analysis. Clin Lymphoma Myeloma Leuk 23(10):733\u2013741. https:\/\/doi.org\/10.1016\/j.clml.2023.06.008","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"5","key":"2945_CR11","doi-asserted-by":"publisher","first-page":"e217","DOI":"10.1016\/S2352-3026(16)00036-3","volume":"3","author":"AJ Ferreri","year":"2016","unstructured":"Ferreri AJ, Cwynarski K, Pulczynski E et al (2016) Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the international extranodal lymphoma study Group-32 (IELSG32) phase 2 trial. Lancet Haematol 3(5):e217\u2013e227. https:\/\/doi.org\/10.1016\/S2352-3026(16)00036-3","journal-title":"Lancet Haematol"},{"key":"2945_CR12","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1007\/s11060-012-0891-7","volume":"109","author":"T Birnbaum","year":"2012","unstructured":"Birnbaum T, Stadler EA, von Baumgarten L, Straube A (2012) Rituximab significantly improves complete response rate in patients with primary CNS lymphoma. J Neurooncol 109:285\u2013291. https:\/\/doi.org\/10.1007\/s11060-012-0891-7","journal-title":"J Neurooncol"},{"issue":"18","key":"2945_CR13","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/S1470-2045(18)30747-2","volume":"20","author":"JEC Bromberg","year":"2019","unstructured":"Bromberg JEC, Issa S, Bakunina K et al (2019) Rituximab in patients with primary CNS lymphoma (HOVON 105\/ALLG NHL 24): a randomised, open-label, phase 3 intergroup study. Lancet Oncol 20(18):216\u2013228","journal-title":"Lancet Oncol"},{"key":"2945_CR14","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1212\/wnl.0000000000000593","volume":"83","author":"M Holdhoff","year":"2014","unstructured":"Holdhoff M, Ambady P, Abdelaziz A et al (2014) High-dose methotrexate with or without rituximab in newly diagnosed primary CNS lymphoma. Neurology 83:235\u2013239. https:\/\/doi.org\/10.1212\/wnl.0000000000000593","journal-title":"Neurology"},{"key":"2945_CR15","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1002\/ajh.24204","volume":"90","author":"R Kansara","year":"2015","unstructured":"Kansara R, Shenkier TN, Connors JM et al (2015) Rituximab with high-dose methotrexate in primary central nervous system lymphoma. Am J Hematol 90:1149\u20131154. https:\/\/doi.org\/10.1002\/ajh.24204","journal-title":"Am J Hematol"},{"key":"2945_CR16","doi-asserted-by":"publisher","first-page":"2777","DOI":"10.3109\/10428194.2016.1167203","volume":"57","author":"H Mocikova","year":"2016","unstructured":"Mocikova H, Pytlik R, Sykorova A et al (2016) Role of rituximab in treatment of patients with primary central nervous system lymphoma: a retrospective analysis of the CZECH lymphoma study group registry. Leuk Lymphoma 57:2777\u20132783. https:\/\/doi.org\/10.3109\/10428194.2016.1167203","journal-title":"Leuk Lymphoma"},{"key":"2945_CR17","doi-asserted-by":"publisher","first-page":"444","DOI":"10.7534\/j.issn.1009-2137.2016","volume":"24","author":"W Luo","year":"2016","unstructured":"Luo W, Ji LH, Geng H et al (2016) Clinical therapeutic efficacy of rituximab combined with methotrexate on primary central nervous system lymphoma. Zhongguo Shi Yan Xue Ye Xue Za Zhi 24:444\u2013447. https:\/\/doi.org\/10.7534\/j.issn.1009-2137.201602.025","journal-title":"Zhongguo Shi Yan Xue Ye Xue Za Zhi"},{"key":"2945_CR18","first-page":"366","volume":"26","author":"J Fu","year":"2021","unstructured":"Fu J, Ma X (2021) High-dose methotrexate combined with rituximab improves the survival rate of patients with primary central nervous system lymphoma. J BUON 26:366\u2013372","journal-title":"J BUON"},{"key":"2945_CR19","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.7534\/j.issn.1009-2137.2017.05.021","volume":"25","author":"K Mou","year":"2017","unstructured":"Mou K, Gu WW, Gu CH, Qi JD (2017) Curative efficacy of high dose MTX combined with Rituxan for treatment primary CNS lymphoma. Zhongguo Shi Yan Xue Ye Xue Za Zhi 25:1406\u20131409. https:\/\/doi.org\/10.7534\/j.issn.1009-2137.2017.05.021","journal-title":"Zhongguo Shi Yan Xue Ye Xue Za Zhi"},{"issue":"8","key":"2945_CR20","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1093\/neuonc\/not032","volume":"15","author":"G Gregory","year":"2013","unstructured":"Gregory G, Arumugaswamy A, Leung T, Chan KL, Abikhair M, Tam C, Bajel A, Cher L, Grigg A, Ritchie D, Opat S (2013) Rituximab is associated with improved survival for aggressive B cell CNS lymphoma. Neuro Oncol 15(8):1068\u20131073. https:\/\/doi.org\/10.1093\/neuonc\/not032","journal-title":"Neuro Oncol"},{"key":"2945_CR21","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1007\/s00277-015-2470-4","volume":"94","author":"M Madle","year":"2015","unstructured":"Madle M, Kr\u00e4mer I, Lehners N et al (2015) The influence of rituximab, high-dose therapy followed by autologous stem cell transplantation, and age in patients with primary CNS lymphoma. Ann Hematol 94:1853\u20131857. https:\/\/doi.org\/10.1007\/s00277-015-2470-4","journal-title":"Ann Hematol"},{"key":"2945_CR22","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s11060-022-04004-9","volume":"158","author":"AB DeAtkine","year":"2022","unstructured":"DeAtkine AB, Abdelrashid M, Tucker Z et al (2022) High-dose methotrexate and rituximab induction regimen in immunocompetent patients with primary CNS lymphoma: a retrospective single-center study of survival predictors. J Neurooncol 158:33\u201340. https:\/\/doi.org\/10.1007\/s11060-022-04004-9","journal-title":"J Neurooncol"},{"key":"2945_CR23","doi-asserted-by":"publisher","DOI":"10.21037\/aol-22-19","volume":"7","author":"P Yerram","year":"2023","unstructured":"Yerram P, Reiss SN, Modelevsky L, Schaff L, Reiner AS, Panageas KS, Grommes C (2023) Is more better? Increased doses of high dose methotrexate and addition of rituximab is associated with improved outcomes in a large primary CNS lymphoma cohort. Ann Lymphoma 7:1. https:\/\/doi.org\/10.21037\/aol-22-19","journal-title":"Ann Lymphoma"},{"key":"2945_CR24","doi-asserted-by":"publisher","first-page":"115068","DOI":"10.1016\/j.ejca.2024.115068","volume":"213","author":"FA de Groot","year":"2024","unstructured":"de Groot FA, Dekker TJA, Doorduijn JK, B\u00f6hringer S, Brink M, de Groen RAL, de Haan LM, Woei-A-Jin FJSH, Noordenbos T, Sijs-Szabo A, Oudshoorn MA, Lam KH, Diepstra A, Te Boome LCJ, Terpstra V, Bohmer LH, Nicolae A, Posthuma EFM, Koens L, Durian MF, Stavast J, van der Poel MWM, Hamid MA, Stevens WBC, van Rooij SLM, Oostvogels RS, M\u00fchlebner A, Neelis KJ, van den Brand M, Tousseyn T, Dierickx D, de Weerdt O, Beeker A, Jansen PM, Kersten MJ, Zijlstra JM, Chamuleau MED, Veelken H, Bromberg JCE, Nijland M, Vermaat JSP (2024) Clinical characteristics and survival outcomes of patients with primary central nervous system lymphoma treated with high-dose methotrexate-based polychemotherapy and consolidation therapies. Eur J Cancer 213:115068. https:\/\/doi.org\/10.1016\/j.ejca.2024.115068","journal-title":"Eur J Cancer"},{"issue":"5","key":"2945_CR25","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1002\/hon.3198","volume":"41","author":"O Bairey","year":"2023","unstructured":"Bairey O, Lebel E, Buxbaum C, Porges T, Taliansky A, Gurion R, Goldschmidt N, Shina TT, Zektser M, Hofstetter L, Siegal T (2023) A retrospective study of 222 patients with newly diagnosed primary central nervous system lymphoma-outcomes indicative for improved survival overtime. Hematol Oncol 41(5):838\u2013847. https:\/\/doi.org\/10.1002\/hon.3198","journal-title":"Hematol Oncol"},{"issue":"4","key":"2945_CR26","doi-asserted-by":"publisher","first-page":"618","DOI":"10.3390\/cancers17040618","volume":"17","author":"JR .Janopaul-Naylor","year":"2025","unstructured":".Janopaul-Naylor JR, Patel JS, Rupji M, Hoang KB, McCall NS, Qian DC, Shoaf ML, Kothari S, Olson JJ, Shu HG, Voloschin A, Zhong J, Neill SG, Eaton B (2025) Impact of systemic and radiation therapy on survival of primary central nervous system lymphoma. Cancers (Basel) 17(4):618. https:\/\/doi.org\/10.3390\/cancers17040618","journal-title":"Cancers (Basel)"},{"issue":"5","key":"2945_CR27","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1007\/s12185-017-2316-z","volume":"106","author":"Y Song","year":"2017","unstructured":"Song Y, Wen Y, Xue W, Zhang Y, Zhang M (2017) Effect of rituximab on primary central nervous system lymphoma: a meta-analysis. Int J Hematol 106(5):612\u2013621. https:\/\/doi.org\/10.1007\/s12185-017-2316-z","journal-title":"Int J Hematol"},{"key":"2945_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2022.103756","volume":"176","author":"Z Lin","year":"2022","unstructured":"Lin Z, Chen X, Liu L, Zeng H, Li Z, Xu B (2022) The role of central nervous system (CNS) prophylaxis in preventing DLBCL patients from CNS relapse: a network meta-analysis. Crit Rev Oncol Hematol 176:103756. https:\/\/doi.org\/10.1016\/j.critrevonc.2022.103756","journal-title":"Crit Rev Oncol Hematol"},{"issue":"5","key":"2945_CR29","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1002\/hon.2666","volume":"37","author":"AM Schmitt","year":"2019","unstructured":"Schmitt AM, Herbrand AK, Fox CP et al (2019) Rituximab in primary central nervous system lymphoma-a systematic review and meta-analysis. Hematol Oncol 37(5):548\u2013557. https:\/\/doi.org\/10.1002\/hon.2666","journal-title":"Hematol Oncol"},{"issue":"2","key":"2945_CR30","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1038\/nrclinonc.2015.152","volume":"13","author":"JB Stone","year":"2016","unstructured":"Stone JB, DeAngelis LM (2016) Cancer-treatment-induced neurotoxicity\u2013focus on newer treatments. Nat Rev Clin Oncol 13(2):92\u2013105. https:\/\/doi.org\/10.1038\/nrclinonc.2015.152","journal-title":"Nat Rev Clin Oncol"},{"issue":"5","key":"2945_CR31","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1182\/blood.2021012932","volume":"139","author":"M Alcantara","year":"2022","unstructured":"Alcantara M, Houillier C, Blonski M et al (2022) CAR T-cell therapy in primary central nervous system lymphoma: the clinical experience of the French LOC network. Blood 139(5):792\u2013796. https:\/\/doi.org\/10.1182\/blood.2021012932","journal-title":"Blood"},{"issue":"1","key":"2945_CR32","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1182\/bloodadvances.2022008525","volume":"7","author":"MR Cook","year":"2023","unstructured":"Cook MR, Dorris CS, Makambi KH et al (2023) Toxicity and efficacy of CAR T-cell therapy in primary and secondary CNS lymphoma: a meta-analysis of 128 patients. Blood Adv 7(1):32\u201339. https:\/\/doi.org\/10.1182\/bloodadvances.2022008525","journal-title":"Blood Adv"},{"issue":"4","key":"2945_CR33","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1182\/blood.2024024168","volume":"144","author":"JK Godfrey","year":"2024","unstructured":"Godfrey JK, Gao L, Shouse G et al (2024) Glofitamab stimulates immune cell infiltration of CNS tumors and induces clinical responses in secondary CNS lymphoma. Blood 144(4):457\u2013461. https:\/\/doi.org\/10.1182\/blood.2024024168","journal-title":"Blood"},{"issue":"12","key":"2945_CR34","doi-asserted-by":"publisher","first-page":"3485","DOI":"10.3324\/haematol.2023.282875","volume":"108","author":"C Lacan","year":"2023","unstructured":"Lacan C, Caron J, Tarantino N et al (2023) CAR T-cell therapy for central nervous system lymphomas: blood and cerebrospinal fluid biology, and outcomes. Haematologica 108(12):3485\u20133490. https:\/\/doi.org\/10.3324\/haematol.2023.282875","journal-title":"Haematologica"}],"container-title":["Acta Neurologica Belgica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13760-025-02945-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13760-025-02945-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13760-025-02945-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T16:11:43Z","timestamp":1785514303000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13760-025-02945-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,10]]},"references-count":34,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["2945"],"URL":"https:\/\/doi.org\/10.1007\/s13760-025-02945-2","relation":{},"ISSN":["0300-9009","2240-2993"],"issn-type":[{"value":"0300-9009","type":"print"},{"value":"2240-2993","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,10]]},"assertion":[{"value":"22 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study is based on previously published data and does not involve any new studies with human participants or animals performed by the authors; therefore, ethics approval was not required.","order":2,"name":"Ethics","label":"<b>Ethics approval<\/b>","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"<b>Consent to participate<\/b>","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"<b>Consent to publish<\/b>","group":{"name":"EthicsHeading","label":"Declarations"}}]}}